Moderna lands US COVID-19 vaccine contract worth up to $8bn

Moderna lands US COVID-19 vaccine contract worth up to $8bn

"It needs to test its COVID-19 vaccines outside its borders because coronavirus cases in China have dwindled and it is harder to find the population diversity required", read the report.

First phase of human trials on a made-in-Vietnam COVID-19 vaccine could begin as early as this October.

Multiple clinical studies of different vaccines are already underway, and a challenge trial is not likely to replace them, the National Institute of Allergy and Infectious Diseases (NIAID) told Reuters.

"We are honored to partner with the United Kingdom government to deliver a vaccine that could provide vital protection in the fight against the global health crisis", Stanley C. Erck, president and chief Executive Officer of Novavax said in a statement.

USA government scientists have begun efforts to manufacture a strain of the novel coronavirus that could be used in human challenge trials of vaccines, a controversial type of study in which healthy volunteers would be vaccinated and then intentionally infected with the virus, Reuters has learned.

The vaccine also produced high levels of antibodies against the SARS-CoV-2 virus after a single dose of the vaccine, with participants who had received two doses possessing higher levels of antibodies compared to recovered COVID-19 patients.

A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020.

If Moderna gets vaccines to the USA government in time to receive incentive payments for timely shipping, it will receive $1.5 billion for the production and delivery of 100 million doses.

The US officials, though, continued their scepticism towards what Russian Federation earlier this week declared as world's first COVID-19 vaccine.

Besides, the two companies and the Ministry of Health and Welfare signed a letter of intent to cooperate in the fast and stable production of NVX-CoV2373, global supply support for equitable distribution for the vaccine, and health improvement through local supply efforts. The FUJIFILM Diosynth Biotechnologies site in the expected to produce about 180 million doses annually, which further boosts the global supply of NVX-CoV2373 for additional markets.

The statement said that the contractual framework would facilitate an initial purchase of 200 million doses on behalf of all European Union member states, and could further purchase an additional 200 million vaccine doses.

The vaccine uses a technology known as recombinant nanoparticle to produce antigens - molecules that are created to spur the immune system into action.

Shares of Moderna have more than tripled since it announced in January it was developing a vaccine.

Related Articles